← k3vl4r
Log inGet started →

BIAF (BioAffinity Technologies Inc) Price Forecast

AI-generated price forecast for BioAffinity Technologies Inc (BIAF) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of November 2026: K3vl4r's calibrated AI forecast currently reads BIAF as 1/1 bearish across its horizons (0 of 1 timeframes pointing up), with a last price of 1.40. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP🔬 Deep research

Last price

1.40

AI outlook

1/1 bearish

Timeframes up

0 / 1

Share𝕏PostTelegram

BIAF forecast by horizon

HorizonDirectionCalibrated move (end of horizon)
1-hour——
4-hour——
Daily~4 weeks out▼ Down-89.56%
WeeklyNot enough track record yet—

Calibrated: each horizon's forecast is weighted by how often the model has called BIAF's direction correctly over the last 30 days, and reversed where it has been wrong more often than right. A horizon votes only once it has enough resolved forecasts.

Latest BIAF news

From the market-news feed the forecasts are read against.

  • BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down · Yahoo · Nov 13
  • bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions · Yahoo · Nov 11
  • bioAffinity Technologies posts record monthly volume for CyPath Lung test · Yahoo · Nov 11
  • bioAffinity posts record month for CyPath Lung cancer test · Yahoo · Nov 11
  • bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test · Yahoo · Nov 11

🔒

See the full BIAF forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

BIAF forecast — frequently asked

Will BIAF go up?

K3vl4r's calibrated AI forecast currently reads BIAF as 1/1 bearish — 0 of 1 forecast horizons point up, so the overall read is leaning to the downside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the BIAF price prediction for 2026?

K3vl4r's model projects BIAF toward $0.1722 over the next ~4 weeks, a -89.6% move from $1.65. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

ACRSPTGXSABSMDHOWLLGVNSYREBBIOVNDAMLYSTRVIDYNAIMCATX

Will BIAF reach…?

Will BIAF reach $2.00?Will BIAF reach $3.00?Will BIAF reach $5.00?Will BIAF reach $10.00?

Or see the full BIAF price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare BIAF

BIAF vs ACRSBIAF vs PTGXBIAF vs SABSBIAF vs MDBIAF vs HOWLBIAF vs LGVN

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rResearch libraryTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.